Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
June 13, 2019 - Amgen and Allergan announced the FDA approval of Kanjinti (trastuzumab-anns), a biosimilar to Genentech’s Herceptin® (trastuzumab).
Download PDF
Return to publications
